| Symbol | APGE |
|---|---|
| Name | APOGEE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 221 CRESCENT STREET,BUILDING 17,SUITE 102B, WALTHAM, Massachusetts, 02453, United States |
| Telephone | +1 650 394-5230 |
| Fax | — |
| — | |
| Website | https://www.apogeetherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001974640 |
| Description | Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. Additional info from NASDAQ: |
Henderson Jane 🔴 sold 15.0K shares of Apogee Therapeutics, Inc. (APGE) Transaction Date: Jul 24, 2026 | Filing ID: 086729
Read moreDambkowski Carl 🔴 sold 8.0K shares of Apogee Therapeutics, Inc. (APGE) Transaction Date: Jul 14, 2026 | Filing ID: 084344
Read moreDirector HENDERSON MICHAEL THOMAS 🔴 sold 95.0K shares of Apogee Therapeutics, Inc. (APGE) at $133.63 ($2.7M) Transaction Date: Jul 08, 2026 | Filing ID: 082758
Read moreDambkowski Carl 🟡 adjusted position in 5.5K shares (1 derivative) of Apogee Therapeutics, Inc. (APGE) at $132.74 Transaction Date: Jul 01, 2026 | Filing ID: 080477
Read moreNew Form PREM14A - Apogee Therapeutics, Inc. <b>Filed:</b> 2026-07-02 <b>AccNo:</b> 0001140361-26-027469 <b>Size:</b> 4 MB
Read moreNew Form DEFA14A - Apogee Therapeutics, Inc. <b>Filed:</b> 2026-06-26 <b>AccNo:</b> 0001140361-26-026601 <b>Size:</b> 43 KB
Read moreDambkowski Carl 🔴 sold 26.4K shares of Apogee Therapeutics, Inc. (APGE) at $132.60 ($3.5M) Transaction Date: Jun 22, 2026 | Filing ID: 077427
Read moreDirector HENDERSON MICHAEL THOMAS 🔴 sold 80.0K shares of Apogee Therapeutics, Inc. (APGE) at $132.54 ($10.6M) Transaction Date: Jun 22, 2026 | Filing ID: 077426
Read moreApogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
Read moreNew Form SCHEDULE 13D/A - Apogee Therapeutics, Inc. <b>Filed:</b> 2026-06-23 <b>AccNo:</b> 0001104659-26-076853 <b>Size:</b> 23 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07027527 | An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990… | Phase1 | Atopic Dermatitis | Active_Not_Recruiting | 2025-06-04 | 2027-12-01 | ClinicalTrials.gov |
| NCT07003425 | A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis | Phase2 | Atopic Dermatitis | Recruiting | 2025-05-14 | 2029-12-01 | ClinicalTrials.gov |
| NCT06920901 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immuno… | Phase1 | Asthma | Active_Not_Recruiting | 2025-03-27 | 2027-03-01 | ClinicalTrials.gov |
| NCT06395948 | A Study Evaluating APG777 in Atopic Dermatitis | Phase2 | Atopic Dermatitis | Active_Not_Recruiting | 2024-04-29 | 2028-06-01 | ClinicalTrials.gov |
| NCT02939807 | A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatoce… | Phase2 | Carcinoma, Hepatocellular | Withdrawn | 2019-09-30 | 2024-01-30 | ClinicalTrials.gov |
| NCT02757326 | ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma | Phase1 | Multiple Myeloma | Terminated | 2016-12-13 | 2019-05-01 | ClinicalTrials.gov |
| NCT02229981 | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffus… | Phase1 | Diffuse Large B Cell Lymphoma | Withdrawn | 2014-07-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT01488513 | ABC294640 in Treating Patients With Advanced Solid Tumors | Phase1 | Pancreatic Cancer | Completed | 2011-08-01 | 2015-07-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06395948 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06395948 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| Dupilumab | Other | Phase PHASE1 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07027527 |
| APG990 | Other | Phase PHASE1 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07027527 |
| APG777 | Other | Phase PHASE1 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07027527 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06395948 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06395948 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06395948 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06395948 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06395948 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06395948 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06395948 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06395948 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06395948 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06395948 |
| ABC294640 | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | WITHDRAWN | NCT02229981 |
| sphingosine kinase-2 inhibitor ABC294640 | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01488513 |
| Opaganib | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT02757326 |
| ABC294640 | Other | Phase PHASE2 | Carcinoma, Hepatocellular | WITHDRAWN | NCT02939807 |
| ABC294640 | Other | Phase PHASE2 | Carcinoma, Hepatocellular | WITHDRAWN | NCT02939807 |
| Placebo | Other | Phase PHASE1 | Asthma | ACTIVE_NOT_RECRUITING | NCT06920901 |
| APG777 | Other | Phase PHASE1 | Asthma | ACTIVE_NOT_RECRUITING | NCT06920901 |
| Dupilumab | Other | Phase PHASE1 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07027527 |
| APG990 | Other | Phase PHASE1 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07027527 |
| APG777 | Other | Phase PHASE1 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07027527 |
| Placebo | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06395948 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06395948 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| APG777 | Other | Phase PHASE2 | Atopic Dermatitis | RECRUITING | NCT07003425 |
| ABC294640 | DRUG | Phase PHASE2 | Carcinoma, Hepatocellular | WITHDRAWN | NCT02939807 |
| Dupilumab | DRUG | Phase PHASE1 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07027527 |
| APG990 | DRUG | Phase PHASE1 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07027527 |
| Placebo | DRUG | Phase PHASE1 | Asthma | ACTIVE_NOT_RECRUITING | NCT06920901 |
| APG777 | DRUG | Phase PHASE1 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07027527 |